Isis Pharmaceuticals (www.isispharm.com) has developed an antisense drug candidate that continues to show potential in treating patients with cardiovascular diseases by reducing cholesterol, LDL-C, as ...
In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's proprietary "brain shuttle" program with the objective of increasing the brain penetration of ASOs with systemic ...
Isis will be responsible for global development of ISIS-SMN Rx through the completion of Phase 2/3 registrational clinical trials, with Biogen Idec providing advice on the clinical trial design and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results